IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i17p10800-d901746.html
   My bibliography  Save this article

Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review

Author

Listed:
  • Alessandra Castelluccia

    (Radiation Oncology, Department of Radiotherapy, Hospital “A. Perrino”, ASL Brindisi, 72100 Brindisi, Italy
    These authors contributed equally to this work.)

  • Pierpaolo Mincarone

    (Institute for Research on Population and Social Policies, National Research Council, 72100 Brindisi, Italy
    MOVE-Mentis s.r.l., 47522 Cesena, Italy
    These authors contributed equally to this work.)

  • Maria Rosaria Tumolo

    (Department of Biological and Environmental Sciences and Technology, University of Salento, 73100 Lecce, Italy)

  • Saverio Sabina

    (MOVE-Mentis s.r.l., 47522 Cesena, Italy
    Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy)

  • Riccardo Colella

    (Department of Engineering for Innovation, University of Salento, 73100 Lecce, Italy)

  • Antonella Bodini

    (Institute for Applied Mathematics and Information Technologies “E. Magenes”, National Research Council, 20133 Milan, Italy)

  • Francesco Tramacere

    (Radiation Oncology, Department of Radiotherapy, Hospital “A. Perrino”, ASL Brindisi, 72100 Brindisi, Italy)

  • Maurizio Portaluri

    (Radiation Oncology, Department of Radiotherapy, Hospital “A. Perrino”, ASL Brindisi, 72100 Brindisi, Italy)

  • Carlo Giacomo Leo

    (MOVE-Mentis s.r.l., 47522 Cesena, Italy
    Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy)

Abstract

Objectives: This review systematically summarizes the evidence on the economic impact of magnetic resonance image-guided RT (MRIgRT). Methods: We systematically searched INAHTA, MEDLINE, and Scopus up to March 2022 to retrieve health economic studies. Relevant data were extracted on study type, model inputs, modeling methods and economic results. Results: Five studies were included. Two studies performed a full economic assessment to compare the cost-effectiveness of MRIgRT with other forms of image-guided radiation therapy. One study performed a cost minimization analysis and two studies performed an activity-based costing, all comparing MRIgRT with X-ray computed tomography image-guided radiation therapy (CTIgRT). Prostate cancer was the target condition in four studies and hepatocellular carcinoma in one. Considering the studies with a full economic assessment, MR-guided stereotactic body radiation therapy was found to be cost effective with respect to CTIgRT or conventional or moderate hypofractionated RT, even with a low reduction in toxicity. Conversely, a greater reduction in toxicity is required to compete with extreme hypofractionated RT without MR guidance. Conclusions: This review highlights the great potential of MRIgRT but also the need for further evidence, especially for late toxicity, whose reduction is expected to be the real added value of this technology.

Suggested Citation

  • Alessandra Castelluccia & Pierpaolo Mincarone & Maria Rosaria Tumolo & Saverio Sabina & Riccardo Colella & Antonella Bodini & Francesco Tramacere & Maurizio Portaluri & Carlo Giacomo Leo, 2022. "Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review," IJERPH, MDPI, vol. 19(17), pages 1-21, August.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10800-:d:901746
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/17/10800/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/17/10800/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Elahe Khorasani & Majid Davari & Abbas Kebriaeezadeh & Farshad Fatemi & Ali Akbari Sari & Vida Varahrami, 2022. "A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1577-1590, December.
    2. Maarten J. IJzerman & Hendrik Koffijberg & Elisabeth Fenwick & Murray Krahn, 2017. "Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature," PharmacoEconomics, Springer, vol. 35(7), pages 727-740, July.
    3. Sorenson, Corinna & Drummond, Michael & Bhuiyan Kahn, Beena, 2013. "Medical technology as a key driver of rising health expenditures: disentangling the relationship," LSE Research Online Documents on Economics 48043, London School of Economics and Political Science, LSE Library.
    4. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Chia-Chin Li & Ying-Chun Lin & Ji-An Liang & K. S. Clifford Chao & Te-Chun Hsia & Chun-Ru Chien, 2023. "Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review," IJERPH, MDPI, vol. 20(6), pages 1-10, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Matthijs M. Versteegh & Isaac Corro Ramos & Nasuh C. Buyukkaramikli & Amir Ansaripour & Vivian T. Reckers-Droog & Werner B. F. Brouwer, 2019. "Severity-Adjusted Probability of Being Cost Effective," PharmacoEconomics, Springer, vol. 37(9), pages 1155-1163, September.
    2. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    3. Wang, Yi & Rattanavipapong, Waranya & Teerawattananon, Yot, 2021. "Using health technology assessment to set priority, inform target product profiles, and design clinical study for health innovation," Technological Forecasting and Social Change, Elsevier, vol. 172(C).
    4. Hareth Al-Janabi & Job van Exel & Werner Brouwer & Joanna Coast, 2016. "A Framework for Including Family Health Spillovers in Economic Evaluation," Medical Decision Making, , vol. 36(2), pages 176-186, February.
    5. Anderson, Pippa & Webb, Philip & Groves, Sam, 2017. "Prioritisation of specialist health care services; not NICE, not easy but it can be done," Health Policy, Elsevier, vol. 121(9), pages 978-985.
    6. Maurizio Bussolo & Johannes Koettl & Emily Sinnott, 2015. "Golden Aging," World Bank Publications - Books, The World Bank Group, number 22018.
    7. Arthur E. Attema & Han Bleichrodt & Olivier L’Haridon & Patrick Peretti-Watel & Valérie Seror, 2018. "Discounting health and money: New evidence using a more robust method," Journal of Risk and Uncertainty, Springer, vol. 56(2), pages 117-140, April.
    8. Soltanzadeh, Javad & Sahebjamnia, Navid & Khosroshahi, Elnaz Mesma & Bouguerra, Abderaouf, 2024. "Commercializing Covid-19 diagnostic technologies: A review of challenges, success factors, and insights from the profiting from innovation framework," Technovation, Elsevier, vol. 130(C).
    9. Júlia Varga, 2017. "Out-migration and attrition of physicians and dentists before and after EU accession (2003 and 2011): the case of Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1079-1093, December.
    10. Blankart, Carl Rudolf & Dams, Florian & Penton, Hannah & Kaló, Zoltán & Zemplényi, Antal & Shatrov, Kosta & Iskandar, Rowan & Federici, Carlo, 2021. "Regulatory and HTA early dialogues in medical devices," Health Policy, Elsevier, vol. 125(10), pages 1322-1329.
    11. Rowan Iskandar & Carlo Federici & Cassandra Berns & Carl Rudolf Blankart, 2022. "An approach to quantify parameter uncertainty in early assessment of novel health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 116-134, September.
    12. Bae, Eun-Young & Hong, Ji-Min & Kwon, Hye-Young & Jang, Suhyun & Lee, Hye-Jae & Bae, SeungJin & Yang, Bong-Min, 2016. "Eight-year experience of using HTA in drug reimbursement: South Korea," Health Policy, Elsevier, vol. 120(6), pages 612-620.
    13. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100038, London School of Economics and Political Science, LSE Library.
    14. Attema, Arthur & Krol, Marieke & van Exel, Job & Brouwer, Werner, 2014. "New findings from the TTO for income approach to elicit willingness to pay for a QALY," MPRA Paper 61197, University Library of Munich, Germany.
    15. Mareike Schad & Jürgen John, 2012. "Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 127-144, April.
    16. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    17. James K. Hammitt, 2012. "Discounting Health And Cost‐Effectiveness Analysis: A Response To Nord," Health Economics, John Wiley & Sons, Ltd., vol. 21(7), pages 878-882, July.
    18. Seksiri NIWATTISAIWONG, 2019. "The Us and High Health Care Spendings: A Comparative Case With OECD on the Three Prominent Factors," RAIS Journal for Social Sciences, Research Association for Interdisciplinary Studies, vol. 3(1), pages 1-11, May.
    19. E. Wetering & N. Exel & J. Rose & R. Hoefman & W. Brouwer, 2016. "Are some QALYs more equal than others?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 117-127, March.
    20. Mike Paulden & Anthony J Culyer, 2010. "Does cost-effectiveness analysis discriminate against patients with short life expectancy? Matters of logic and matters of context," Working Papers 055cherp, Centre for Health Economics, University of York.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10800-:d:901746. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.